Adial Pharmaceuticals
Charlottesville
About Adial Pharmaceuticals
Adial Pharmaceuticals engages in the development of prescription medications for addiction and related disorders in the United States. The company's research pipeline includes AD04, a compound that completed the Phase IIb study for the treatment of alcohol use disorders; and AD01, which completed the Phase I clinical-stage for treating addictive behaviors.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $10K – $50K
- Total funding: $40.7M
- Funding stage: IPO
- Last round: Post-IPO Equity (Jun 2025)
- Ticker: nasdaq:ADIL
- Website: adialpharma.com
- Phone: 434-422-9800
Industries & Categories
Addiction Treatment, Biotechnology, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/adial-pharmaceuticals-141412 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.